Evaluation of potential inflammatory biomarkers of disease severity in psoriasis: a case control study
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20262839Keywords:
Psoriasis, Biomarkers, Disease severityAbstract
Background: Psoriasis is a chronic inflammatory skin disorder affecting approximately 2-4% of the global population, characterized by immune dysregulation and keratinocyte hyperproliferation. Although multiple investigations have identified potential biomarkers, no validated panel exists for assessing disease severity. Objectives of the study were to determine levels of serum uric acid (SUA), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), CRP/albumin ratio (CAR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in psoriasis patients versus controls, and assess their correlation with disease severity using psoriasis area severity index (PASI).
Methods: This case-control study included 50 psoriasis patients and 50 age- and sex-matched controls. Participants underwent complete blood count, CRP, ESR, serum albumin, and SUA measurements. Disease severity was categorized as mild (PASI <7), moderate (PASI 7-15), or severe (PASI >15).
Results: ESR was significantly elevated in cases versus controls (33.24±22.75 versus 19.44±11.50 mm/hour, p<0.001). CAR distribution differed significantly (p<0.001), with 56% of cases having CAR ≤0.1 mg/l versus 2% of controls. SUA showed no overall difference between groups (p=0.468) but significantly correlated with disease severity (p=0.028), increasing from mild (4.76±0.97 mg/dl) to moderate (5.47±1.50 mg/dl) to severe disease (5.77±1.01 mg/dl). CRP, albumin, NLR, and PLR showed no significant differences.
Conclusions: ESR and CAR significantly differentiate psoriasis patients from controls. SUA, while not discriminating between cases and controls, correlates with disease severity. These cost-effective biomarkers can complement clinical assessment in psoriasis management.
References
Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021;21(3):170-3. DOI: https://doi.org/10.7861/clinmed.2021-0257
Ramessur R, Corbett M, Marshall D, Acencio ML, Barbosa IA, Dand N, et al. Biomarkers of disease progression in people with psoriasis: a scoping review. Br J Dermatol. 2022;187(4):481-93. DOI: https://doi.org/10.1111/bjd.21627
Tampa M, Mitran MI, Mitran CI, Matei C, Georgescu SR. Psoriasis: What is new in markers of disease severity? Medicina (Kaunas). 2024;60(2):337. DOI: https://doi.org/10.3390/medicina60020337
Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles KE, Tian S, Cardinale I, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677-87. DOI: https://doi.org/10.1038/jid.2010.340
Rodríguez-Cerdeira C, Molares-Vila A, Sánchez-Blanco E, Sánchez-Blanco B. Study on certain biomarkers of inflammation in psoriasis through "OMICS" platforms. Open Biochem J. 2014;8:21-34. DOI: https://doi.org/10.2174/1874091X01408010021
Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25(6):510-8. DOI: https://doi.org/10.1016/j.clindermatol.2007.08.003
Kar BR, Sathishkumar D, Tahiliani S, Parthasarathi A, Neema S, Ganguly S, et al. Biomarkers in Psoriasis: The Future of Personalised Treatment. Indian J Dermatol. 2024;69(3):256-63. DOI: https://doi.org/10.4103/ijd.ijd_167_24
Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2013;72:104-10. DOI: https://doi.org/10.1136/annrheumdis-2012-203037
Balta S, Celik T, Mikhailidis DP, Ozturk C, Dermikol S, Aparci M, et al. The relation between atherosclerosis and the neutrophil-lymphocyte ratio. Clin Appl Thromb Hemost. 2016;22:405-11. DOI: https://doi.org/10.1177/1076029615569568
Özer S, Yılmaz R, Sönmezgöz E, Karaaslan E, Taskin S, Butun I, et al. Simple markers for subclinical inflammation in patients with familial mediterranean fever. Med Sci Monit. 2015;21:298-303. DOI: https://doi.org/10.12659/MSM.892289
Kanbay M, Solak Y, Dogan E, Lanaspa MA, Covic A. Uric acid in hypertension and renal disease: the chicken or the egg? Blood Purif. 2010;30(4):288-95. DOI: https://doi.org/10.1159/000321074
Lubrano E, Cantini F, Costanzo A, Girolomoni G, Prignano F, Olivieri I et al. Measuring psoriatic disease in clinical practice. An expert opinion position paper. Autoimmun Rev. 2015;14:864-74. DOI: https://doi.org/10.1016/j.autrev.2015.05.010
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification and management of Psoriasisand associated comorbodity (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-85. DOI: https://doi.org/10.1038/jid.2012.339
Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010;76:595-601. DOI: https://doi.org/10.4103/0378-6323.72443
Gökalp H, Akyüz A. Levels of C-reactive protein, uric acid and parameters related to lipid metabolism in patients with psoriasis. J Health Sci Med. 2021;4:160-4.
Kopeć-Pyciarz K, Malewska-Kasprzak M, Brycht P, Owczarek A. The influence of systemic treatment on the endothelial function and oxidative stress in patients with psoriasis. Postepy Dermatol Alergol. 2021;38:759-66.
Sheikh G, Masood Q, Majeed S, Hassan I. Comparison of levels of serum albumin in patients of psoriasis with controls. Indian Dermatol Online J. 2015;6:396-9.
Kemeriz F. Could the C-reactive protein/albumin ratio be a new severity marker in psoriasis? Dermatol Ther. 2022;35:e15289.
Balta I, Balta S, Demirkol S, Mikhailidis DP, Celik T, Akhan M et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169:1066-70. DOI: https://doi.org/10.1111/bjd.12525
Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC et al. C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159(2):322-30. DOI: https://doi.org/10.1111/j.1365-2133.2008.08628.x
Gisondi P, Targher G, Cagalli A, Girolomoni G. Hyperuricemia in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;70(1):127-30. DOI: https://doi.org/10.1016/j.jaad.2013.09.005
Li X, Miao X, Wang H, Wang Y, Li F, Yang Q, et al. Association of serum uric acid levels in psoriasis: A systematic review and meta-analysis. Medicine (Baltimore). 2016;95(19):e3676. DOI: https://doi.org/10.1097/MD.0000000000003676
Billiet L, Doaty S, Katz JD, Velasquez MT. Review of hyperuricemia as new marker for metabolic syndrome. ISRN Rheumatol. 2014;2014:852954. DOI: https://doi.org/10.1155/2014/852954
Kim DS, Shin D, Lee MS, Kim HJ, Kim DY, Kim SM, et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016;43(3):305-10. DOI: https://doi.org/10.1111/1346-8138.13061
Polat M, Bugdayci G, Kaya H, Oğuzman H. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in Turkish patients with chronic plaque psoriasis. Acta Dermatovenerol Alp Pannonica Adriat. 2017;26(4):97-100. DOI: https://doi.org/10.15570/actaapa.2017.28
Paliogiannis P, Satta R, Deligia G, Farina G, Bassu S, Mangoni AA, et al. Associations between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratios and the presence and severity of psoriasis: a systematic review and meta-analysis. Clin Exp Med. 2019;19(1):37-45. DOI: https://doi.org/10.1007/s10238-018-0538-x
Kemeriz F, Tugrul B, Tuncer SC. C- reactive protein toalbumin ratio: Is a new parameter for the disease severity in patients with psoriasis vulgaris? Dermatol Sin. 2020;38(4):199-204. DOI: https://doi.org/10.4103/ds.ds_42_20
Solak B, Dickicier BS, Erdem T. Impact of elevated serum uric acid levels on systemic inflammation in patients with psoriasis. Angiology. 2016;67(9):870-6.
Mishra S, Kadhur M, Jartarkar SR, Keloji H, Agarwal R, Babu S. Correlation between serum uric acid, C- reactive protein, and neutrophil-to-lymphocyte ratio in patients with psoriasis: A case- control study. Turkderm- Turk Arch Dermatol Venerol. 2022;56(1):28-33. DOI: https://doi.org/10.4274/turkderm.galenos.2021.69797
Downloads
Published
How to Cite
Issue
Section
